| Long name: |
CHMP2A Primary Polyclonal Antibody |
| Also known as: |
CHMP2A PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
CHMP2A |
| Specificity: |
This is a highly specific antibody against CHMP2A |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
20-50/222 |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human CHMP2A |
| Gene ID number: |
27243 |
| Swiss Prot: |
O43633 |
| Tested Applications: |
IF(IHC-P), IHC-P |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
-I, ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released, Involved in HIV-1 p6- and p9-dependent virus release, MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, The ESCRT machinery also functions in topologically equivalent membrane fission events, The MVB pathway appears to require the sequential function of ESCRT-O, lysosomal enzymes and lipids, possibly in conjunction with the AAA ATPase VPS4, such as stimulated growth factor receptors, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses), -II and -III complexes, Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
BC-2, CHMP2, CHMP2a, Charged multivesicular body protein 2a, Chromatin-modifying protein 2a, Putative breast adenocarcinoma marker BC-2, VPS2, VPS2A, Vacuolar protein sorting-associated protein 2-1, Vps2-1, hVps2-1, BC2 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
CHMP2A |
| Short name: |
CHMP2A Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
CHMP2A (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
30216 |
| Gene: |
CHMP2A |
More about : CHMP2A |
| Long gene name: |
charged multivesicular body protein 2A |
| Synonyms gene name: |
chromatin modifying protein 2A |
| Synonyms: |
BC-2 CHMP2 VPS2 VPS2A |
| Synonyms name: |
cerevisiae) , putative breast adenocarcinoma marker (32kD) VPS2 homolog A (S |
| Locus: |
19q13, 43 |
| Discovery year: |
2005-04-04 |
| GenBank acession: |
AF042384 |
| Entrez gene record: |
27243 |
| Pubmed identfication: |
15173323 11559748 |
| RefSeq identity: |
NM_014453 |
| Classification: |
Charged multivesicular body proteins ESCRT-III |
| Havana BLAST/BLAT: |
OTTHUMG00000183547 |